Profile Response Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

Molecular Profile CD274 positive
Therapy Eribulin + Pembrolizumab
Indication/Tumor Type triple-receptor negative breast cancer
Response Type predicted - sensitive


  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")


  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
CD274 positive triple-receptor negative breast cancer predicted - sensitive Eribulin + Pembrolizumab Phase Ib/II Actionable In a Phase I/II trial, Keytruda (pembrolizumab) and Eribulin combination therapy demonstrated safety and clinical activity in patients with metastatic triple-negative breast cancer, patients with CD274 (PD-L1)-positive tumors achieved better objective response rate (28.4% vs 17.3%), median progression-free survival (4.2 vs 3.9 months), and overall survival (16.3 vs 15.2 months) compared to patients with CD274 (PD-L1)-negative tumors (PMID: 33727258; NCT02513472). 33727258
PubMed Id Reference Title Details
(33727258) Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study. Full reference...